Biohaven Ltd. (NYSE:BHVN)’s traded shares stood at 1.85 million during the last session. At the close of trading, the stock’s price was $13.77, to imply a decrease of -4.71% or -$0.68 in intraday trading. The BHVN share’s 52-week high remains $20.57, putting it -49.38% down since that peak but still an impressive 59.77% since price per share fell to its 52-week low of $5.54. The company has a valuation of $938.58M, with an average of 1.15 million shares in intraday trading volume over the past 10 days and average of 1.01 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Biohaven Ltd. (BHVN), translating to a mean rating of 1.60. Of 6 analyst(s) looking at the stock, 0 analyst(s) give BHVN a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$1.22.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Biohaven Ltd. (NYSE:BHVN) trade information
After registering a -4.71% downside in the last session, Biohaven Ltd. (BHVN) has traded red over the past five days. The stock hit a weekly high of 15.07 this Friday, 03/17/23, dropping -4.71% in its intraday price action. The 5-day price performance for the stock is 4.00%, and -20.77% over 30 days. With these gigs, the year-to-date price performance is -0.79%. Short interest in Biohaven Ltd. (NYSE:BHVN) saw shorts transact 6.4 million shares and set a 7.21 days time to cover.
Analysts on Wall Street suggest a consensus price target of $24.60, implying an increase of 44.02% to the stock’s current value. The extremes give us $23.00 and $27.00 for target low and target high price respectively. As such, BHVN has been trading -96.08% off suggested target high and -67.03% from its likely low.
Biohaven Ltd. (BHVN) estimates and forecasts
Looking at statistics comparing Biohaven Ltd. share performance against respective industry, we note that the company has outperformed competitors.
BHVN Dividends
Biohaven Ltd. has its next earnings report out between May 08 and May 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Biohaven Ltd. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Biohaven Ltd. (NYSE:BHVN)’s Major holders
Biohaven Ltd. insiders hold 14.67% of total outstanding shares, with institutional holders owning 94.28% of the shares at 110.49% float percentage. In total, 94.28% institutions holds shares in the company, led by Stifel Financial Corporation. As of Dec 30, 2022, the company held over 5.62 million shares (or 8.24% of shares), all amounting to roughly $77.38 million.
The next major institution holding the largest number of shares is State Street Corporation with 4.59 million shares, or about 6.74% of shares outstanding. As of the market price on Dec 30, 2022, these shares were worth $63.22 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Fidelity Select Portfolios – Biotechnology as the top two Mutual Funds with the largest holdings of the Biohaven Ltd. (BHVN) shares. Going by data provided on Dec 30, 2022, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 3.45 million shares. This is just over 5.06% of the total shares, with a market valuation of $47.49 million. Data from the same date shows that the other fund manager holds a little less at 2.82 million, or 4.14% of the shares, all valued at about 38.88 million.
